Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 4 - The Untold Story

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

The UK’s First Diabetic Giant Anteater Has Been Fitted With A Glucose Monitor

The first diabetic giant anteater in the United Kingdom has been fitted with a monitor to check its blood glucose levels – which is normally used on humans.

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 20.9% on an annualized basis producing an average annual return of 27.35%. Currently, DexCom has a market capitalization of $30.77 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $16,000 Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 64.52% on an annualized basis producing an average annual return of 74.42%. Currently, DexCom has a market capitalization of $115.32 billion.

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 22.06% on an annualized basis producing an average annual return of 28.95%. Currently, DexCom has a market capitalization of $29.24 billion.

What Are Whales Doing With DexCom

A whale with a lot of money to spend has taken a noticeably bearish stance on DexCom. Looking at options history for DexCom (NASDAQ:DXCM) we detected 25 strange trades.

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

inkl

Read news from The Economist, FT, and more,
with one subscription

DexCom Earnings Perspective: Return On Invested Capital

DexCom Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, DexCom (NASDAQ:DXCM) posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters.

If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today

If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.

Read Here Why Did This Analyst Cut DexCom's Price Target

Read Here Why Did This Analyst Cut DexCom's Price Target

Recap: DexCom Q1 Earnings

Recap: DexCom Q1 Earnings

DexCom (NASDAQ:DXCM) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by 38.46%, reporting an EPS of $0.32 versus an estimate of $0.52.

DexCom's Earnings: A Preview

DexCom's Earnings: A Preview

DexCom (NASDAQ:DXCM) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that DexCom will report an earnings per share (EPS) of $0.52.

Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today

Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of $49.71 billion.

Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark

Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark

DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has

Get all your
news in one place.

100's of premium titles.
One news app.

DexCom's Glucose Monitoring System Snags Breakthrough Device Tag For Hospital Use

2 Upgraded Diabetes Stocks to Add to Your Watchlist

Diabetes has become one of the leading causes of death for Americans, claiming more than 100,000 lives in 2021. But the disease’s prevalence represents promising prospects for the diabetes care devices market. Given this backdrop, analysts have recently upgraded diabetes stocks DexCom (DXCM) and Insulet (PODD). Thus, these stocks could…

10 Biggest Price Target Changes For Wednesday

Raymond James cut DexCom, Inc. (NASDAQ: DXCM) price target from $618 to $538. DexCom shares rose 1.1% to $434.60 in pre-market trading.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Delta Air Lines

Truist Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

398,614 stories

144,560 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play